Please try another search
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. The company is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is headquartered in Berlin, Germany.
Name | Age | Since | Title |
---|---|---|---|
Daniel Douglas Von Hoff | 76 | 2021 | Member of Scientific Advisory Board |
Eileen M. O’Reilly | - | 2021 | Member of Scientific Advisory Board |
Maurizio PetitBon | 77 | 2016 | Independent Chairman of the Supervisory Board |
Jose Saro | - | 2021 | Chairman of Scientific Advisory Board |
Gabriela E. Chiorean | - | 2021 | Member of Scientific Advisory Board |
Thomas T. W. Seufferlein | - | 2021 | Member of Scientific Advisory Board |
Monika E. Hegi | - | 2022 | Member of Scientific Advisory Board |
Michael Lim | - | 2022 | Member of Scientific Advisory Board |
Cornelis Alexander Izeboud | 53 | 2020 | Independent Member of Supervisory Board |
Susan Coles | 57 | 2021 | Independent Deputy Chair of Supervisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review